Isaac Francis

Regis Resources (ASX:RRL) has reported a strong preliminary, unaudited update for the December 2025 quarter, highlighting robust production and a record increase in cash and bullion.

Capricorn Metals (ASX:CMM) reported a strong operational performance at its Karlawinda Gold Project in the December 2025 quarter.

Marvell Technology said on Tuesday it will buy networking equipment provider XConn Technologies in a deal worth ​about $540 million, as the chipmaker doubles down on data center hardware ‌amid a race to expand artificial intelligence infrastructure.

Ford Motor Company (NYSE:F) reported robust U.S. sales results for the fourth quarter and full year 2025, with Q4 sales rising 2.7% year-over-year and annual sales climbing 6% to approximately 2.2 million vehicles.

Genprex (NASDAQ:GNPX) announced landmark preliminary preclinical data on January 6, 2026, for its diabetes gene therapy candidate, GPX-002.

Telegram reported operating revenue of $870 million in the first half of 2025, marking a 65% increase from $525 million a year earlier, according to the Financial Times.

Stereotaxis (NYSE:STXS), a global leader in endovascular surgical robotics, announced on Tuesday, January 6, 2026, that it has received U.S. Food and Drug Administration (FDA) approval for its MAGiC™ Magnetic Interventional Ablation Catheter.

Profound Medical Corp. (NASDAQ:PROF) on Tuesday announced that Johns Hopkins Hospital has performed its first commercial prostate cancer treatment using the company's TULSA-PRO system, marking a key adoption milestone for the MRI-guided, incision-free ablation technology.

Lithium Argentina AG (NYSE:LAR) shares are in focus after the company announced standout preliminary 2025 results for its Cauchari-Olaroz operation.

The project, a joint venture with Ganfeng Lithium, achieved full-year production of 34,100 tonnes of lithium carbonate—reaching the upper limit of its 30,000–35,000 tonne guidance.

AngioDynamics (NASDAQ:ANGO) on Tuesday reported fiscal second-quarter results that highlighted continued momentum in its high-margin Med Tech portfolio, with overall net sales rising 8.8% year over year to $79.4 million for the period ended Nov. 30, 2025.